Brolucizumab versus aflibercept in treating exudative age-related macular degeneration: a 12-month pro re nata regimen

Abstract We compared 12-month treatment outcomes of intravitreal injections of brolucizumab (IVBr) with aflibercept (IVA) for treatment-naïve exudative age-related macular degeneration (AMD). Patients were given three monthly IVBr or IVA injections and were followed up monthly for 12 months. Additio...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Wataru Kikushima, Yoichi Sakurada, Yoshiko Fukuda, Seigo Yoneyama, Yumi Kotoda, Daphne Viel Tsuru, Kenji Kashiwagi
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Nature Portfolio 2026-01-01
Edice:	Scientific Reports
Témata:	Age-related macular degeneration Polypoidal choroidal vasculopathy Brolucizumab Aflibercept Recurrence
On-line přístup:	https://doi.org/10.1038/s41598-026-34984-x
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!